Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
| ▸ | ELOC | Q15369 | 1/20 | 0.32 |
| ▸ | ELOB | Q15370 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237661 | 0.78 | HPGD (0.38) | ALDH1A1MAPTSLC6A4 | |
| SCHEMBL13369794 | 0.76 | PTPN1 (0.35) | ALDH1A1MAPT | |
| SCHEMBL4988272 | 0.76 | L3MBTL1 (0.43) | ALDH1A1MAPTSLC6A4RHEB | |
| SCHEMBL483135 | 0.76 | MAPT (0.43) | TSHRALDH1A1MAPT | |
| SCHEMBL5761245 | 0.74 | TSHR (0.59) | TSHRLTA4HTOP2ATOP2BALDH1A1 | |
| SCHEMBL2423602 | 0.73 | — | — | |
| SCHEMBL10887327 | 0.73 | TSHR (0.48) | TSHRLTA4HTOP2ATOP2BALDH1A1 | |
| SCHEMBL21952148 | 0.72 | ALDH1A1 (0.47) | TSHRALDH1A1MAPT | |
| SCHEMBL3145115 | 0.72 | DDAH1 (0.50) | ALDH1A1MAPTSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2172892 | 0.71 | APOBEC3G (0.52) | ALDH1A1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2076503-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | disclosed |
| WO-2007136116-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | TSHR 2437/4885LTA4H 3839/4885TOP2A 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.